Effects of fetuin-A with diverse functions and multiple mechanisms on human health.

  title={Effects of fetuin-A with diverse functions and multiple mechanisms on human health.},
  author={Mehmet Arif Icer and Hilal Yıldıran},
  journal={Clinical biochemistry},

A narrative review of exosomes in vascular calcification.

The roles of exosomes are described including in the promotion of extracellular mineral deposits, induction of phenotypic conversion of vascular smooth muscle cells (VSMCs), transport of microRNA between cells, and regulation on autophagy and oxidative stress, with the aim of providing novel ideas for the clinical diagnosis and treatment of VC.

Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease

The crosstalk and interaction between hepatokine, stellakines, adipokines, and myokines and NF-κB in NAFLD is discussed and the therapeutic potential of silymarin inNAFLD/NASH is explored.

Matrix Vesicles as a Therapeutic Target for Vascular Calcification

The detailed role of MVs in the progression of VC is reviewed and the difference with other major drivers of calcification, including aging, uremia, mechanical stress, oxidative stress, and inflammation is compared.

Fetuin-A and risk of diabetes-related vascular complications: a prospective study

The data show that lower plasma fetuin-A levels measured prior to the diagnosis of diabetes may be etiologically implicated in the development of diabetes-associated microvascular disease.

Causal association pathways between fetuin-A and kidney function: a mediation analysis

A possible role of fetuin-A in the etiology of declining renal function through mediating body mass index, uric acid, diabetes mellitus, and hypertension via complex causal pathways is revealed.

Effect of Combined Antiretroviral Therapy on the Levels of Selected Parameters Reflecting Metabolic and Inflammatory Disturbances in HIV-Infected Patients

The obtained results indicated significant changes in the expression of selected parameters in the course of HIV infection and cART, and there is need for further research on the clinical usefulness of the selected parameters.

Fetuin-A expression in human umbilical vein endothelial cells and amnion cells of patients with gestational diabetes mellitus.

There is a correlation between fetal macrosomia, neonatal hypoglycemia, placental weight, and fetuin-A expression of HUVECs in patients with GDM.

Organokines in Rheumatoid Arthritis: A Critical Review

Changes in the pattern of organokines secretion were identified, and these could directly or indirectly contribute to aggravating RA, promoting articular alterations, and predicting the disease activity.

Serum levels of fetuin-A as a novel biomarker for disease activity in patients with Takayasu arteritis and granulomatous polyangiitis

Serum Fetuin-A was negatively correlated with CRP, BVAS, and ITAS scores and significantly decreased in vasculitis patients with high disease activity and also that it might also be a predictor of long-term cardiovascular progression.

Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications

It is hypothesized that the effects of NAFLD are not only limited to the structural and functional changes in the liver but may also involve the entire body via the hepatic factors, e.g., playing an important role in the development of AKI.



Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review

The protein has been shown to highly exacerbate insulin resistance (IR) through blocking insulin-stimulated glucose transporter 4 (GLUT-4) translocation and protein kinase B (Akt) activation, and appeared to interfere with downstream phosphorylation events in insulin receptor and insulin receptor substrate signaling.

Fetuin-A – Alpha2-Heremans-Schmid Glycoprotein: From Structure to a Novel Marker of Chronic Diseases Part 2. Fetuin-A – A Marker of Insulin Resistance and Related Chronic Diseases

Summary Fetuin-A is a secretory liver glycoprotein with multiple physiological functions such as regulation of insulin resistance, tissue calcification, bone metabolism, cellular proteolytic

Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes

Fetuin-A that is synthesized, modified, and secreted by tumor cells may be more relevant in understanding the pathophysiological role of this enigmatic protein in tumors, as opposed to the relatively high serum concentrations of the liver derived protein.

Effects of nutritional status on serum fetuin-A level

It is indicated that high blood glucose levels increase hepatic fetuin-A release by activating extracellular signal-regulated kinase 1/2 enzymes and increased plasma free acids do the same effect by increasing NF-KB activity.

Fetuin-A: a novel link between obesity and related complications

Evidence suggests that elevated FetA level causes impaired glycemic control, as FetA has been implicated in impairment of insulin receptor signaling, toll-like receptor 4 activation, macrophage migration and polarization, adipocyte dysfunction, hepatocyte triacylglycerol accumulation and liver inflammation and fibrosis.

Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification.

Evidence is provided that the uptake of the serum protein fetuin-A by VSMC is a key event in the inhibition of vesicle-mediated VSMC calcification, a condition associated with an elevated circulating calcium x phosphate product in patients with ESRD.

Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature.

Fetuin-A has a diagnostic potential as a biomarker for liver dysfunction, cardiovascular diseases and disorders associated with metabolic syndrome and may be a marker of liver function and predictor of mortality in patients with cirrhosis and hepatocellular cancer.

A Hepatic Protein, Fetuin-A, Occupies a Protective Role in Lethal Systemic Inflammation

Experimental data suggest that fetuin-A is protective against lethal systemic inflammation partly by inhibiting active HMGB1 release.

The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.

A critical role is demonstrated of the serum protein alpha2-Heremans-Schmid glycoprotein (Ahsg) as an inhibitor of unwanted mineralization and a novel therapeutic concept to prevent ectopic calcification accompanying various diseases is provided.